Annual SG&A
$52.79 M
-$17.27 M-24.65%
31 December 2023
Summary:
Ligand Pharmaceuticals Incorporated annual selling, general & administrative expenses is currently $52.79 million, with the most recent change of -$17.27 million (-24.65%) on 31 December 2023. During the last 3 years, it has fallen by -$7.22 million (-12.03%). LGND annual SG&A is now -31.00% below its all-time high of $76.51 million, reached on 31 December 2004.LGND Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$24.48 M
+$6.85 M+38.88%
30 September 2024
Summary:
Ligand Pharmaceuticals Incorporated quarterly selling, general & administrative expenses is currently $24.48 million, with the most recent change of +$6.85 million (+38.88%) on 30 September 2024. Over the past year, it has increased by +$9.82 million (+67.00%). LGND quarterly SG&A is now -21.38% below its all-time high of $31.13 million, reached on 31 December 2022.LGND Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
$2.16 B
+$45.24 M+2.14%
30 September 2024
Summary:
Ligand Pharmaceuticals Incorporated TTM selling, general & administrative expenses is currently $2.16 billion, with the most recent change of +$45.24 million (+2.14%) on 30 September 2024. Over the past year, it has increased by +$2.09 billion (+3079.04%). LGND TTM SG&A is now at all-time high.LGND TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LGND Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -24.6% | +67.0% | +3079.0% |
| 3 y3 years | -12.0% | +92.4% | +3186.6% |
| 5 y5 years | +39.9% | +157.0% | +4949.1% |
LGND Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -24.6% | +12.8% | -21.4% | +247.5% | at high | +27.2% |
| 5 y | 5 years | -24.6% | +39.9% | -21.4% | +247.5% | at high | +108.0% |
| alltime | all time | -31.0% | +654.1% | -21.4% | +157.6% | at high | +156.4% |
Ligand Pharmaceuticals Incorporated Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $24.48 M(+38.9%) | $69.04 M(+16.6%) |
| June 2024 | - | $17.62 M(+60.9%) | $59.22 M(+12.0%) |
| Mar 2024 | - | $10.95 M(-31.5%) | $52.89 M(+0.2%) |
| Dec 2023 | $52.79 M(-24.7%) | $15.99 M(+9.1%) | $52.79 M(-22.3%) |
| Sept 2023 | - | $14.66 M(+29.8%) | $67.93 M(-0.4%) |
| June 2023 | - | $11.29 M(+4.0%) | $68.19 M(-1.2%) |
| Mar 2023 | - | $10.86 M(-65.1%) | $68.99 M(-1.5%) |
| Dec 2022 | $70.06 M(+49.7%) | $31.13 M(+108.7%) | $70.06 M(+52.4%) |
| Sept 2022 | - | $14.92 M(+23.4%) | $45.97 M(+5.0%) |
| June 2022 | - | $12.09 M(+1.4%) | $43.77 M(-5.7%) |
| Mar 2022 | - | $11.93 M(+69.3%) | $46.40 M(-1.5%) |
| Dec 2021 | $46.79 M(-22.0%) | $7.04 M(-44.6%) | $47.09 M(-28.3%) |
| Sept 2021 | - | $12.72 M(-13.5%) | $65.70 M(-3.4%) |
| June 2021 | - | $14.71 M(+16.6%) | $68.01 M(+7.3%) |
| Mar 2021 | - | $12.62 M(-50.8%) | $63.37 M(+5.6%) |
| Dec 2020 | $60.01 M(+43.3%) | $25.66 M(+70.8%) | $60.01 M(+34.5%) |
| Sept 2020 | - | $15.02 M(+49.2%) | $44.63 M(+14.0%) |
| June 2020 | - | $10.07 M(+8.7%) | $39.13 M(-2.3%) |
| Mar 2020 | - | $9.26 M(-9.9%) | $40.06 M(-4.4%) |
| Dec 2019 | $41.88 M(+11.0%) | $10.28 M(+7.9%) | $41.88 M(-2.1%) |
| Sept 2019 | - | $9.53 M(-13.4%) | $42.77 M(-0.3%) |
| June 2019 | - | $10.99 M(-0.8%) | $42.88 M(+4.1%) |
| Mar 2019 | - | $11.09 M(-0.7%) | $41.18 M(+9.1%) |
| Dec 2018 | $37.73 M(+31.7%) | $11.16 M(+15.9%) | $37.73 M(+9.9%) |
| Sept 2018 | - | $9.63 M(+3.6%) | $34.32 M(+8.2%) |
| June 2018 | - | $9.29 M(+21.6%) | $31.72 M(+9.5%) |
| Mar 2018 | - | $7.64 M(-1.4%) | $28.97 M(+1.1%) |
| Dec 2017 | $28.65 M(+3.6%) | $7.75 M(+10.2%) | $28.65 M(+3.4%) |
| Sept 2017 | - | $7.03 M(+7.4%) | $27.70 M(+1.8%) |
| June 2017 | - | $6.55 M(-10.6%) | $27.22 M(-2.5%) |
| Mar 2017 | - | $7.32 M(+7.8%) | $27.90 M(+0.9%) |
| Dec 2016 | $27.65 M(+8.9%) | $6.79 M(+3.7%) | $27.65 M(-1.5%) |
| Sept 2016 | - | $6.55 M(-9.5%) | $28.06 M(+6.0%) |
| June 2016 | - | $7.24 M(+2.4%) | $26.48 M(+0.0%) |
| Mar 2016 | - | $7.07 M(-1.9%) | $26.47 M(+4.2%) |
| Dec 2015 | $25.40 M(+12.5%) | $7.21 M(+45.0%) | $25.40 M(+7.1%) |
| Sept 2015 | - | $4.97 M(-31.2%) | $23.71 M(-7.0%) |
| June 2015 | - | $7.22 M(+20.5%) | $25.48 M(+8.5%) |
| Mar 2015 | - | $5.99 M(+8.6%) | $23.49 M(+4.1%) |
| Dec 2014 | $22.57 M(+25.5%) | $5.52 M(-18.2%) | $22.57 M(+5.1%) |
| Sept 2014 | - | $6.74 M(+28.7%) | $21.47 M(+10.2%) |
| June 2014 | - | $5.24 M(+3.3%) | $19.49 M(+5.0%) |
| Mar 2014 | - | $5.07 M(+14.8%) | $18.55 M(+3.2%) |
| Dec 2013 | $17.98 M(+14.0%) | $4.42 M(-7.1%) | $17.98 M(+1.2%) |
| Sept 2013 | - | $4.76 M(+10.5%) | $17.77 M(+2.6%) |
| June 2013 | - | $4.31 M(-4.4%) | $17.32 M(+2.7%) |
| Mar 2013 | - | $4.50 M(+7.1%) | $16.87 M(+6.9%) |
| Dec 2012 | $15.78 M(+8.2%) | $4.20 M(-2.4%) | $15.78 M(+5.9%) |
| Sept 2012 | - | $4.31 M(+11.6%) | $14.90 M(+2.4%) |
| June 2012 | - | $3.86 M(+12.9%) | $14.56 M(+0.0%) |
| Mar 2012 | - | $3.42 M(+2.8%) | $14.55 M(-0.2%) |
| Dec 2011 | $14.58 M(+13.7%) | $3.32 M(-16.2%) | $14.58 M(-1301.3%) |
| Sept 2011 | - | $3.96 M(+2.8%) | -$1.21 M(-108.8%) |
| June 2011 | - | $3.85 M(+11.9%) | $13.79 M(+4.3%) |
| Mar 2011 | - | $3.44 M(-127.6%) | $13.23 M(+3.1%) |
| Dec 2010 | $12.83 M(-57.9%) | -$12.48 M(-165.8%) | $12.83 M(-54.7%) |
| Sept 2010 | - | $18.97 M(+476.5%) | $28.33 M(+4.9%) |
| June 2010 | - | $3.29 M(+7.9%) | $27.01 M(+1.7%) |
| Mar 2010 | - | $3.05 M(+0.9%) | $26.55 M(-12.4%) |
| Dec 2009 | $30.45 M | $3.02 M(-82.9%) | $30.32 M(-0.6%) |
| Sept 2009 | - | $17.65 M(+523.5%) | $30.50 M(+62.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2009 | - | $2.83 M(-58.5%) | $18.78 M(-8.4%) |
| Mar 2009 | - | $6.82 M(+112.6%) | $20.50 M(-13.8%) |
| Dec 2008 | $23.79 M(-21.8%) | $3.21 M(-45.9%) | $23.79 M(-2.7%) |
| Sept 2008 | - | $5.93 M(+30.3%) | $24.45 M(+4.6%) |
| June 2008 | - | $4.55 M(-54.9%) | $23.38 M(-11.3%) |
| Mar 2008 | - | $10.10 M(+160.9%) | $26.34 M(-13.4%) |
| Dec 2007 | $30.41 M(-30.7%) | $3.87 M(-20.3%) | $30.41 M(-24.6%) |
| Sept 2007 | - | $4.86 M(-35.4%) | $40.31 M(-15.6%) |
| June 2007 | - | $7.52 M(-46.9%) | $47.75 M(-3.1%) |
| Mar 2007 | - | $14.17 M(+2.9%) | $49.26 M(+12.2%) |
| Dec 2006 | $43.91 M(+89.8%) | $13.77 M(+12.0%) | $43.91 M(-456.0%) |
| Sept 2006 | - | $12.29 M(+36.1%) | -$12.33 M(+418.9%) |
| June 2006 | - | $9.03 M(+2.5%) | -$2.38 M(-115.1%) |
| Mar 2006 | - | $8.81 M(-120.7%) | $15.71 M(-53.6%) |
| Dec 2005 | $23.13 M(-69.8%) | -$42.47 M(-290.9%) | $33.85 M(-57.9%) |
| Sept 2005 | - | $22.25 M(-17.9%) | $80.46 M(-4.2%) |
| June 2005 | - | $27.11 M(+0.6%) | $84.03 M(+2.4%) |
| Mar 2005 | - | $26.95 M(+550.5%) | $82.03 M(+7.2%) |
| Dec 2004 | $76.51 M(+23.6%) | $4.14 M(-83.9%) | $76.51 M(-19.5%) |
| Sept 2004 | - | $25.81 M(+2.8%) | $95.05 M(+15.3%) |
| June 2004 | - | $25.12 M(+17.2%) | $82.45 M(+16.3%) |
| Mar 2004 | - | $21.44 M(-5.5%) | $70.91 M(+14.6%) |
| Dec 2003 | $61.90 M(+48.0%) | $22.69 M(+71.7%) | $61.90 M(+23.0%) |
| Sept 2003 | - | $13.22 M(-2.6%) | $50.34 M(+5.1%) |
| June 2003 | - | $13.57 M(+9.2%) | $47.89 M(+7.4%) |
| Mar 2003 | - | $12.43 M(+11.7%) | $44.59 M(+6.6%) |
| Dec 2002 | $41.83 M(+21.5%) | $11.12 M(+3.3%) | $41.83 M(+7.6%) |
| Sept 2002 | - | $10.77 M(+4.7%) | $38.88 M(+10.1%) |
| June 2002 | - | $10.28 M(+6.4%) | $35.32 M(+4.1%) |
| Mar 2002 | - | $9.66 M(+18.1%) | $33.93 M(-1.4%) |
| Dec 2001 | $34.43 M(+0.9%) | $8.18 M(+13.5%) | $34.43 M(+0.0%) |
| Sept 2001 | - | $7.21 M(-18.9%) | $34.42 M(-3.8%) |
| June 2001 | - | $8.89 M(-12.5%) | $35.78 M(-1.9%) |
| Mar 2001 | - | $10.16 M(+24.2%) | $36.47 M(+6.9%) |
| Dec 2000 | $34.11 M(+25.2%) | $8.18 M(-4.5%) | $34.10 M(+3.1%) |
| Sept 2000 | - | $8.56 M(-10.6%) | $33.08 M(+8.4%) |
| June 2000 | - | $9.57 M(+22.8%) | $30.52 M(+4.7%) |
| Mar 2000 | - | $7.79 M(+8.9%) | $29.15 M(+6.9%) |
| Dec 1999 | $27.26 M(+64.2%) | $7.16 M(+19.3%) | $27.26 M(+1.7%) |
| Sept 1999 | - | $6.00 M(-26.8%) | $26.80 M(+8.9%) |
| June 1999 | - | $8.20 M(+39.0%) | $24.60 M(+24.9%) |
| Mar 1999 | - | $5.90 M(-11.9%) | $19.70 M(+18.7%) |
| Dec 1998 | $16.60 M(+64.4%) | $6.70 M(+76.3%) | $16.60 M(+31.7%) |
| Sept 1998 | - | $3.80 M(+15.2%) | $12.60 M(+11.5%) |
| June 1998 | - | $3.30 M(+17.9%) | $11.30 M(+6.6%) |
| Mar 1998 | - | $2.80 M(+3.7%) | $10.60 M(+5.0%) |
| Dec 1997 | $10.10 M(-1.0%) | $2.70 M(+8.0%) | $10.10 M(-1.9%) |
| Sept 1997 | - | $2.50 M(-3.8%) | $10.30 M(+4.0%) |
| June 1997 | - | $2.60 M(+13.0%) | $9.90 M(0.0%) |
| Mar 1997 | - | $2.30 M(-20.7%) | $9.90 M(-2.9%) |
| Dec 1996 | $10.20 M(+27.5%) | $2.90 M(+38.1%) | $10.20 M(+9.7%) |
| Sept 1996 | - | $2.10 M(-19.2%) | $9.30 M(-1.1%) |
| June 1996 | - | $2.60 M(0.0%) | $9.40 M(+38.2%) |
| Mar 1996 | - | $2.60 M(+30.0%) | $6.80 M(+15.3%) |
| Dec 1995 | $8.00 M(+14.3%) | $2.00 M(-9.1%) | $5.90 M(0.0%) |
| Sept 1995 | - | $2.20 M(+29.4%) | $5.90 M(-16.9%) |
| Mar 1995 | - | $1.70 M(-15.0%) | $7.10 M(+1.4%) |
| Dec 1994 | $7.00 M | $2.00 M(+17.6%) | $7.00 M(+40.0%) |
| Sept 1994 | - | $1.70 M(0.0%) | $5.00 M(+51.5%) |
| June 1994 | - | $1.70 M(+6.3%) | $3.30 M(+106.3%) |
| Mar 1994 | - | $1.60 M | $1.60 M |
FAQ
- What is Ligand Pharmaceuticals Incorporated annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated annual SG&A year-on-year change?
- What is Ligand Pharmaceuticals Incorporated quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated quarterly SG&A year-on-year change?
- What is Ligand Pharmaceuticals Incorporated TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated TTM SG&A year-on-year change?
What is Ligand Pharmaceuticals Incorporated annual selling, general & administrative expenses?
The current annual SG&A of LGND is $52.79 M
What is the all time high annual SG&A for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high annual selling, general & administrative expenses is $76.51 M
What is Ligand Pharmaceuticals Incorporated annual SG&A year-on-year change?
Over the past year, LGND annual selling, general & administrative expenses has changed by -$17.27 M (-24.65%)
What is Ligand Pharmaceuticals Incorporated quarterly selling, general & administrative expenses?
The current quarterly SG&A of LGND is $24.48 M
What is the all time high quarterly SG&A for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high quarterly selling, general & administrative expenses is $31.13 M
What is Ligand Pharmaceuticals Incorporated quarterly SG&A year-on-year change?
Over the past year, LGND quarterly selling, general & administrative expenses has changed by +$9.82 M (+67.00%)
What is Ligand Pharmaceuticals Incorporated TTM selling, general & administrative expenses?
The current TTM SG&A of LGND is $2.16 B
What is the all time high TTM SG&A for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high TTM selling, general & administrative expenses is $95.05 M
What is Ligand Pharmaceuticals Incorporated TTM SG&A year-on-year change?
Over the past year, LGND TTM selling, general & administrative expenses has changed by +$2.09 B (+3079.04%)